NASDAQ$ARWR
Arrowhead Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
Arrowhead Pharmaceuticals reported its fiscal first quarter 2025 earnings, highlighting a significant licensing agreement with Sarepta Therapeutics and the acceptance of its NDA for plozasiran by the U.S. FDA.
Arrowhead Pharmaceuticals reported a net loss of $173.085 million for the fiscal first quarter ended December 31, 2024, with total revenue of $2.5 million. The company emphasized its strategic achievements, including a major licensing deal with Sarepta Therapeutics worth up to $10 billion in potential milestones and the FDA's acceptance of its plozasiran NDA, positioning it for future growth and potential commercial launches.
- Arrowhead signed and closed a licensing and collaboration agreement with Sarepta Therapeutics, receiving $825 million upfront ($500 million cash, $325 million equity investment) and eligibility for up to $10 billion in potential milestone payments.
- The U.S. FDA accepted the New Drug Application (NDA) for investigational plozasiran for familial chylomicronemia syndrome, with a PDUFA action date of November 18, 2025.
- Plozasiran's NDA submission is supported by positive findings from the Phase 3 PALISADE study, which met its primary and all key secondary endpoints, including significant reductions in triglycerides and acute pancreatitis incidence.
- The company initiated Phase 1/2a clinical trials for ARO-INHBE and ARO-ALK7, both investigational RNAi therapeutics for obesity, and presented interim results for ARO-CFB for complement-mediated diseases.
Headline financials
Revenue & EPS history
Arrowhead Pharmaceuticals · Revenue · Quarterly
$2.5K
Forward guidance
Arrowhead Pharmaceuticals is well-positioned for growth with plans for an independent commercial launch in 2025 and potential for multiple partner launches over the coming few years. The company is funded into 2028 with further cash runway potential from wholly owned candidates.
Tailwinds
- Independent commercial launch planned for 2025.
- Potential for multiple partner launches in the coming years.
- Phase 3 studies of plozasiran in severe hypertriglyceridemia are on pace to be fully enrolled in 2025 with potential study completion in 2026.
- Emerging high-value potential in obesity and CNS programs entering early clinical studies.
- Currently funded into 2028 with further cash runway potential from wholly owned candidates providing opportunities for additional partnerships.
Headwinds
- The report does not explicitly state negative forward guidance. However, potential risks include the impact of the ongoing COVID-19 pandemic on business.
- Safety and efficacy of product candidates are subject to ongoing evaluation.
- Decisions of regulatory authorities and the timing thereof could impact program timelines.
- The duration and impact of regulatory delays in clinical programs remain a risk.
- The likelihood and timing of future milestone and licensing fees are not guaranteed.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.0%
Avg return
Earnings day
+4.2%
Avg return
5 days after
+10.8%
Avg return
30 days after
38%
24 / 64 earnings
Positive
+39.2%
Q4 2024
Best reaction
-26.7%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | +1.6% | +0.1% | -6.1% | |
| Q1 2026 | -0.2% | -4.8% | -7.5% | |
| Q4 2025 | +23.2% | +20.2% | +49.9% | |
| Q2 2025 | +9.4% | +12.5% | +16.1% | |
| Q1 2025 | -5.2% | +0.2% | -24.3% | |
| Q4 2024 | +39.2% | +38.5% | +3.9% | |
| Q3 2024 | -6.4% | -8.6% | -11.1% | |
| Q2 2024 | -12.5% | -9.2% | -5.2% | |
| Q1 2024 | -1.2% | +1.7% | +3.7% | |
| Q4 2023 | -26.7% | -13.8% | +5.8% | |
| Q3 2023 | -13.1% | -8.8% | -7.7% | |
| Q2 2023 | +12.5% | +15.8% | -2.9% | |
| Q1 2023 | -8.5% | -9.9% | -19.3% | |
| Q4 2022 | +1.7% | +15.0% | +27.3% | |
| Q3 2022 | +3.6% | +2.5% | -11.1% | |
| Q2 2022 | -11.5% | -3.3% | -0.7% | |
| Q1 2022 | -11.1% | -5.4% | -22.1% | |
| Q4 2021 | -0.3% | +1.3% | -1.8% | |
| Q3 2021 | -2.0% | -7.4% | +2.2% | |
| Q2 2021 | -5.4% | -5.5% | +3.2% | |
| Q1 2021 | +12.6% | +11.8% | -14.1% | |
| Q4 2020 | -12.2% | -8.4% | +24.1% | |
| Q3 2020 | -7.0% | -8.5% | -18.3% | |
| Q2 2020 | -0.3% | +5.0% | -0.5% | |
| Q1 2020 | -6.4% | -2.4% | -23.9% | |
| Q4 2019 | +37.6% | +48.4% | +31.2% | |
| Q3 2019 | -2.1% | -0.2% | +17.6% | |
| Q2 2019 | +8.0% | +0.1% | +50.2% | |
| Q1 2019 | +13.2% | +25.4% | +33.0% | |
| Q4 2018 | +11.2% | +4.8% | +9.8% | |
| Q3 2018 | +13.2% | +18.6% | +36.2% | |
| Q2 2018 | +15.8% | +27.2% | +33.5% | |
| Q1 2018 | -6.2% | -3.4% | +30.9% | |
| Q4 2017 | -3.1% | -10.5% | +43.6% | |
| Q3 2017 | +8.9% | +13.6% | +69.2% | |
| Q2 2017 | +13.5% | +6.4% | +3.8% | |
| Q1 2017 | +3.2% | +3.7% | +12.1% | |
| Q4 2016 | +0.0% | -1.6% | +62.2% | |
| Q3 2016 | -1.2% | +1.0% | +29.7% | |
| Q2 2016 | -3.1% | — | — | |
| Q1 2016 | -0.9% | — | — | |
| Q4 2015 | -1.1% | — | — | |
| Q3 2015 | +12.1% | — | — | |
| Q2 2015 | -10.9% | — | — | |
| Q1 2015 | -1.1% | — | — | |
| Q4 2014 | -6.2% | — | — | |
| Q3 2014 | +1.2% | — | — | |
| Q2 2014 | -10.7% | — | — | |
| Q1 2014 | -2.6% | — | — | |
| Q4 2013 | +7.3% | — | — | |
| Q3 2013 | +2.5% | — | — | |
| Q2 2013 | +10.2% | — | — | |
| Q1 2013 | -1.8% | — | — | |
| Q4 2012 | -7.2% | — | — | |
| Q3 2012 | -16.8% | — | — | |
| Q2 2012 | -4.5% | — | — | |
| Q1 2012 | -1.4% | — | — | |
| Q4 2011 | +0.5% | — | — | |
| Q2 2011 | +0.5% | — | — | |
| Q3 2011 | -12.4% | — | — | |
| Q3 2010 | -12.4% | — | — | |
| Q4 2010 | -12.4% | — | — | |
| Q1 2011 | -5.6% | — | — | |
| Q2 2010 | -8.1% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro